Hydromorphone abuse-resistant - Acura Pharmaceuticals

Drug Profile

Hydromorphone abuse-resistant - Acura Pharmaceuticals

Alternative Names: LIMITX Hydromorphone; Limitx™ abuse-resistant hydromorphone; LTX-04

Latest Information Update: 12 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Acura Pharmaceuticals
  • Class Morphine derivatives; Opioid analgesics; Small molecules
  • Mechanism of Action Opioid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Pain

Most Recent Events

  • 28 Jun 2017 Pharmacokinetics data from a phase I trial (Study 401) in healthy volunteers released by Acura Pharmaceuticals
  • 18 May 2017 Acura Pharmaceuticals initiates enrolment in a phase I trial for Pain (In volunteers), before May 2017
  • 31 Mar 2017 Acura Pharmaceuticals plans a pharmacokinetic study for pain in the USA in the second quarter of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top